Protein that directs cholesterol traffic identified

By Bob Beale

(Medical Xpress) -- A protein that directs traffic within human cells has been identified as playing a key role in the accumulation of so-called “bad” cholesterol, according to a new study.

Little is known about how this is transported inside a cell, notes Associate Professor Rob Yang, a member of a UNSW research team writing in the journal Cell Reports.

“Cholesterol is carried around our bloodstream, packaged in particles called lipoproteins,

Cholesterol from the low-density lipoproteins - also known as ‘bad’ cholesterol - enters our cells and deposits at different locations through a poorly-understood maze of transport routes,” says Professor Yang, and ARC Future Fellow in the UNSW School of Biotechnology and Biomolecular Sciences.

The lead author on the paper was Postdoctoral Research Fellow Robin Du. Other authors were Abdulla Kazim and Associate Professor Andrew Brown.

The team found that the – known as Hrs - plays a specific role in directing how and where low-density lipoproteins are deposited. The researchers showed in experiments that reducing the amount of Hrs causes cholesterol to accumulate in endosomes, a cellular compartment usually containing little cholesterol.

“This discovery provides a better understanding of how cells handle cholesterol,” he says. “Misdirection of cholesterol will cause it to accumulate in the wrong places in a cell, resulting in disturbed cholesterol metabolism and eventual cell death.

“This will in turn contribute to the development of heart disease, and a number of neurological disorders including Alzheimer’s disease and Parkinson’s disease.”

The team is now trying to identify other factors that may co-operate with Hrs to help direct cholesterol traffic, and in turn may point towards new therapeutic strategies against heart and neurodegenerative diseases.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Organovo has 3D-printed liver tissue for drug testing

Nov 20, 2014

(Medical Xpress)—The commercial release of 3D printed liver tissue was announced earlier this week. Organovo is the company behind the release. The product is intended for use for preclinical drug discovery ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.